Literature DB >> 27612437

Dynamic Phosphorylation of the Myocyte Enhancer Factor 2Cα1 Splice Variant Promotes Skeletal Muscle Regeneration and Hypertrophy.

Fiorenza Baruffaldi1, Didier Montarras2, Valentina Basile1, Luca De Feo1, Sara Badodi1, Massimo Ganassi3, Renata Battini1, Carmine Nicoletti4,5, Carol Imbriano1, Antonio Musarò4,5, Susanna Molinari1.   

Abstract

The transcription factor MEF2C (Myocyte Enhancer Factor 2C) plays an established role in the early steps of myogenic differentiation. However, the involvement of MEF2C in adult myogenesis and in muscle regeneration has not yet been systematically investigated. Alternative splicing of mammalian MEF2C transcripts gives rise to two mutually exclusive protein variants: MEF2Cα2 which exerts a positive control of myogenic differentiation, and MEF2Cα1, in which the α1 domain acts as trans-repressor of the MEF2C pro-differentiation activity itself. However, MEF2Cα1 variants are persistently expressed in differentiating cultured myocytes, suggesting a role in adult myogenesis. We found that overexpression of both MEF2Cα1/α2 proteins in a mouse model of muscle injury promotes muscle regeneration and hypertrophy, with each isoform promoting different stages of myogenesis. Besides the ability of MEF2Cα2 to increase differentiation, we found that overexpressed MEF2Cα1 enhances both proliferation and differentiation of primary myoblasts, and activates the AKT/mTOR/S6K anabolic signaling pathway in newly formed myofibers. The multiple activities of MEF2Cα1 are modulated by phosphorylation of Ser98 and Ser110, two amino acid residues located in the α1 domain of MEF2Cα1. These specific phosphorylations allow the interaction of MEF2Cα1 with the peptidyl-prolyl isomerase PIN1, a regulator of MEF2C functions. Overall, in this study we established a novel regulatory mechanism in which the expression and the phosphorylation of MEF2Cα1 are critically required to sustain the adult myogenesis. The described molecular mechanism will represent a new potential target for the development of therapeutical strategies to treat muscle-wasting diseases. Stem Cells 2017;35:725-738.
© 2016 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Entities:  

Keywords:  Alternative splicing; Differentiation; Hypertrophy; MEF2 transcription factors; Myogenesis; Peptidyl-prolyl isomerase; Phosphorylation; Pin1; Tissue regeneration

Mesh:

Substances:

Year:  2016        PMID: 27612437     DOI: 10.1002/stem.2495

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  14 in total

Review 1.  Emerging roles for MEF2 in brain development and mental disorders.

Authors:  Ahlem Assali; Adam J Harrington; Christopher W Cowan
Journal:  Curr Opin Neurobiol       Date:  2019-05-23       Impact factor: 6.627

2.  MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.

Authors:  Sarah M Judge; Michael R Deyhle; Daria Neyroud; Rachel L Nosacka; Andrew C D'Lugos; Miles E Cameron; Ravneet S Vohra; Ashley J Smuder; Brandon M Roberts; Chandler S Callaway; Patrick W Underwood; Stephen M Chrzanowski; Abhinandan Batra; Meghan E Murphy; Jonathan D Heaven; Glenn A Walter; Jose G Trevino; Andrew R Judge
Journal:  Cancer Res       Date:  2020-03-04       Impact factor: 12.701

3.  Targeted splice sequencing reveals RNA toxicity and therapeutic response in myotonic dystrophy.

Authors:  Matthew K Tanner; Zhenzhi Tang; Charles A Thornton
Journal:  Nucleic Acids Res       Date:  2021-02-26       Impact factor: 16.971

4.  [Construction of an adenovirus vector expressing engineered splicing factor for regulating alternative splicing of YAP1 in neonatal rat cardiomyocytes].

Authors:  Y Li; Q Zhao; X Song; J Song
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-07-20

5.  The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness.

Authors:  Eros Di Giorgio; Elisa Franforte; Sebastiano Cefalù; Sabrina Rossi; Angelo Paolo Dei Tos; Monica Brenca; Maurizio Polano; Roberta Maestro; Harikrishnareddy Paluvai; Raffaella Picco; Claudio Brancolini
Journal:  PLoS Genet       Date:  2017-04-18       Impact factor: 5.917

Review 6.  Diversification of the muscle proteome through alternative splicing.

Authors:  Kiran Nakka; Claudia Ghigna; Davide Gabellini; F Jeffrey Dilworth
Journal:  Skelet Muscle       Date:  2018-03-06       Impact factor: 4.912

Review 7.  Alternative Splicing of Transcription Factors Genes in Muscle Physiology and Pathology.

Authors:  Carol Imbriano; Susanna Molinari
Journal:  Genes (Basel)       Date:  2018-02-19       Impact factor: 4.096

8.  MBNL1 reverses the proliferation defect of skeletal muscle satellite cells in myotonic dystrophy type 1 by inhibiting autophagy via the mTOR pathway.

Authors:  Kai-Yi Song; Xiu-Ming Guo; Hui-Qi Wang; Lei Zhang; Si-Yuan Huang; Ying-Chao Huo; Gang Zhang; Jin-Zhou Feng; Rong-Rong Zhang; Yue Ma; Qing-Zhe Hu; Xin-Yue Qin
Journal:  Cell Death Dis       Date:  2020-07-18       Impact factor: 8.469

9.  Deletion of metal transporter Zip14 (Slc39a14) produces skeletal muscle wasting, endotoxemia, Mef2c activation and induction of miR-675 and Hspb7.

Authors:  Jinhee Kim; Tolunay Beker Aydemir; Felix R Jimenez-Rondan; Courtney H Ruggiero; Min-Hyun Kim; Robert J Cousins
Journal:  Sci Rep       Date:  2020-03-04       Impact factor: 4.379

Review 10.  Transcription Factors in Cancer: When Alternative Splicing Determines Opposite Cell Fates.

Authors:  Silvia Belluti; Giovanna Rigillo; Carol Imbriano
Journal:  Cells       Date:  2020-03-20       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.